Targeting oncogenic drivers in melanoma, the combination of atezolizumab with cobimetinib (anti-MEK) and vemurafenib (anti-BRAF) has been approved for BRAF-V600E-mutant melanoma (Ascierto et al., 2023). Here, BRAF is linked to melanoma.